

Horizon's leading products, services and licensing solutions are now part of Revvity's portfolio.

Research use only. Not for use in diagnostic procedures.

Dharmacon™ Reagents

Edit-R[™] lentiviral Cas9 nuclease expression particles

Requirements

2 vials × 25 μ L (50 μ L total) lentiviral particles in tubes, minimum titer within 10% of \geq 1 × 10⁷ TU/mL (transducing units per mL)

Itemized list of contents

Lentiviral Particles (net quantity 0.025 mL per vial) Dry Ice (net quantity 15 kg)

Edit-R lentiviral Cas9 nuclease expression particles

Cat #	Item description	Lot number_Titer*	Volume	Qty
VCAS10124	hCMV-Blast-Cas9 Nuclease	V22051306_3.62 × 10 ⁷ TU/mL V24020902_1.10 × 10 ⁸ TU/mL	25 μL	2
VCAS10125	mCMV-Blast-Cas9 Nuclease	V20112006_1.24 × 10^8 TU/mL V23060902_7.41 × 10^7 TU/mL	25 μL	2
VCAS10126	hEF1α-Blast-Cas9 Nuclease	V22110403_8.22 × 10 ⁷ TU/mL V23050502_1.37 × 10 ⁸ TU/mL V23081706_2.52 × 10 ⁷ TU/mL	25 μL	2
VCAS10127	mEF1α-Blast-Cas9 Nuclease	V18082303_5.21 × 10 ⁷ TU/mL V23060903_3.38 × 10 ⁷ TU/mL	25 μL	2
VCAS10128	PGK-Blast-Cas9 Nuclease	V21010806_6.86 × 10 ⁷ TU/mL	25 μL	2
VCAS10129	CAG-Blast-Cas9 Nuclease	V22051303_2.90 × 10 ⁷ TU/mL V23050503_6.46 × 10 ⁷ TU/mL V23081806_3.66 × 10 ⁷ TU/mL V23100606_4.43 x 107 TU/mL	25 μL	2
VCAS11227	Inducible-hEF1α-Blast-Cas9 Nuclease	V22120206_4.93 × 10 ⁷ TU/mL V23060903_8.45 × 10 ⁷ TU/mL V23072806_1.31 × 10 ⁷ TU/mL V23100605_5.20 × 10 ⁷ TU/mL V24011906_3.57 × 10 ⁷ TU/mL	25 μL	2
VCAS11862	mCMV-TurboGFP-Cas9 Nuclease	V21061001_8.79 × 10 ⁷ TU/mL	25 μL	2
VCAS11863	mCMV-mKate2-Cas9 Nuclease	V23060803_3.05 × 10 ⁷ TU/mL	25 μL	2
VCAS11864	hEF1α-TurboGFP-Cas9 Nuclease	V23050306_2.36 × 10^7 TU/mL V23072709_3.04 × 10^7 TU/mL V23120806_2.81 x 10^7 TU/mL	25 μL	2
VCAS11865	hEF1α-mKate2-Cas9 Nuclease	V21012205_2.18 × 10 ⁷ TU/mL V22092303_1.01 × 10 ⁷ TU/mL V23060206_7.10 × 10 ⁷ TU/mL V23081805_1.41 × 10 ⁷ TU/mL V24020903_1.33 × 10 ⁷ TU/mL	25 μL	2
VCAS11868	hCMV-TurboGFP-Cas9 Nuclease	V21031806_8.44 × 10 ⁷ TU/mL V23072106_1.96 × 10 ⁷ TU/mL V24012706_1.25 × 10 ⁷ TU/mL	25 μL	2
VCAS11869	hCMV-mKate2-Cas9 Nuclease	V20032002_4.76 × 10 ⁷ TU/mL V24011603_4.86 × 10 ⁷ TU/mL	25 μL	2

Shipping and storage

Store at −80° C. Edit-R™ Lentiviral Cas9 Nuclease Expression Particles are shipped frozen on dry ice and should be stored in a −80° C freezer immediately upon arrival. Lentiviral particles will remain stable for at least one year without any appreciable loss in titer. When ready to use, thaw the lentiviral particles on ice. The lentiviral titers indicated above for each sample are determined from an aliquot that has been through one freeze-thaw. The vials in this package have not been thawed; therefore, the indicated titers are accurate for the first thaw. However, every subsequent freeze-thaw may result in a decrease in titer of two– to five–fold. Any lentiviral particles remaining after the first thaw can be aliquoted into smaller volumes and stored at −80° C.

Classification of Edit-R lentiviral cas9 nuclease expression particles

Lentiviral particles are not capable of causing permanent disability, life-threatening or fatal disease in otherwise healthy humans or animals, and therefore are not classified as infectious substances under IATA and DOT guidelines.

Description of goods

Replication-incompetent, viral-like particles of human, mouse and/or rat origin; intended use is for research purposes only. Proper packaging and labeling of shipments will be utilized to ensure safe and timely transit of lentiviral particle products.

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.

